February 2022—Biodesix announced the launch of its GeneStrat NGS genomic test, a blood-based tumor profiling test. The 52-gene panel includes guideline-recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others.
The GeneStrat NGS test is paired with variant interpretation technology connected to a knowledge database developed by PierianDx. Physicians receive a streamlined report, including genomic insights, in a 72-hour turnaround time. The test is paid by Medicare under the National Coverage Determination for NGS Manual 90.2 section D by Novitas Solutions.
The company also announced the launch of its IQLung Treatment Guidance Testing Strategy. It includes the GeneStrat NGS and provides a broader view of a patient’s disease state. The testing strategy also includes blood-based proteomic and genomic testing workflows for early- and advanced-stage lung cancer that can aid physicians in making treatment decisions. Biodesix plans to add tests, which are in development, to the IQLung portfolio.
Biodesix, 303-417-0500